Published in J Virol on November 01, 1990
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. J Virol (1991) 4.74
Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. J Virol (1994) 4.65
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol (1995) 4.45
The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol (1995) 4.19
Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol (1996) 4.15
The human immunodeficiency virus type 1 encapsidation site is a multipartite RNA element composed of functional hairpin structures. J Virol (1996) 3.91
Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants. J Virol (1993) 3.75
Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol (1995) 3.69
Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc Natl Acad Sci U S A (1992) 3.19
High rate of recombination throughout the human immunodeficiency virus type 1 genome. J Virol (2000) 3.09
Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc Natl Acad Sci U S A (1996) 3.07
Mutant human immunodeficiency virus type 1 genomes with defects in RNA dimerization or encapsidation. J Virol (1997) 2.86
Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection. J Virol (1996) 2.82
An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol (1998) 2.73
Analysis of the assembly function of the human immunodeficiency virus type 1 gag protein nucleocapsid domain. J Virol (1998) 2.71
Human immunodeficiency virus vectors for inducible expression of foreign genes. J Virol (1992) 2.70
Mutational analysis of cis-acting packaging signals in human immunodeficiency virus type 1 RNA. J Virol (1994) 2.68
Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol (1994) 2.51
Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots. J Virol (2002) 2.50
A block to human immunodeficiency virus type 1 assembly in murine cells. J Virol (2000) 2.47
High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J Virol (1998) 2.47
Conditional infectivity of a human immunodeficiency virus matrix domain deletion mutant. J Virol (1993) 2.42
Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases env incorporation into particles and fusogenicity and infectivity. J Virol (1993) 2.34
Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity. J Virol (1992) 2.30
Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther (2005) 2.21
Nucleocapsid protein effects on the specificity of retrovirus RNA encapsidation. J Virol (1995) 2.20
Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes. J Virol (1994) 2.18
Expression of the human immunodeficiency virus type 1 (HIV-1) nef gene during HIV-1 production increases progeny particle infectivity independently of gp160 or viral entry. J Virol (1995) 2.08
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol (2011) 2.01
Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol (1998) 1.97
As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity. J Virol (2003) 1.94
Effects of nucleocapsid mutations on human immunodeficiency virus assembly and RNA encapsidation. J Virol (1997) 1.83
Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. J Virol (1995) 1.78
Genetic assay for multimerization of retroviral gag polyproteins. J Virol (1992) 1.74
Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J Virol (1997) 1.72
Regulation of polyadenylation in human immunodeficiency virus (HIV): contributions of promoter proximity and upstream sequences. EMBO J (1992) 1.68
Importance of ribosomal frameshifting for human immunodeficiency virus type 1 particle assembly and replication. J Virol (1998) 1.61
Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J Virol (1999) 1.58
Endocytosis is a critical step in entry of subgroup B avian leukosis viruses. J Virol (2002) 1.57
Mouse-human heterokaryons support efficient human immunodeficiency virus type 1 assembly. J Virol (2001) 1.55
Structural analysis of human immunodeficiency virus type 1 Gag protein interactions, using cysteine-specific reagents. J Virol (1996) 1.55
Use of a novel human immunodeficiency virus type 1 reporter virus expressing human placental alkaline phosphatase to detect an alternative viral receptor. J Virol (1995) 1.51
Simian immunodeficiency virus variants with differential T-cell and macrophage tropism use CCR5 and an unidentified cofactor expressed in CEMx174 cells for efficient entry. J Virol (1997) 1.49
Inducible human immunodeficiency virus type 1 packaging cell lines. J Virol (1996) 1.49
Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor. J Virol (1997) 1.47
Mutations in the human immunodeficiency virus type 1 integrase D,D(35)E motif do not eliminate provirus formation. J Virol (1998) 1.44
The blocks to human immunodeficiency virus type 1 Tat and Rev functions in mouse cell lines are independent. J Virol (1993) 1.34
A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness. Proc Natl Acad Sci U S A (2005) 1.32
Analysis of minimal human immunodeficiency virus type 1 gag coding sequences capable of virus-like particle assembly and release. J Virol (1998) 1.32
Development of multigene and regulated lentivirus vectors. J Virol (2000) 1.30
Genetic dissociation of the encapsidation and reverse transcription functions in the 5' R region of human immunodeficiency virus type 1. J Virol (1999) 1.29
Structural interactions between retroviral Gag proteins examined by cysteine cross-linking. J Virol (1995) 1.25
Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism. J Virol (2007) 1.22
Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop. AIDS Res Hum Retroviruses (2010) 1.21
Gene transfer into mammalian cells by a Rous sarcoma virus-based retroviral vector with the host range of the amphotropic murine leukemia virus. J Virol (1996) 1.19
Role of the HIV gp120 conserved domain 1 in processing and viral entry. J Biol Chem (2008) 1.19
The conserved carboxy terminus of the capsid domain of human immunodeficiency virus type 1 gag protein is important for virion assembly and release. J Virol (2004) 1.18
Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection. J Virol (2009) 1.17
PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J Virol (2004) 1.15
Expression of human endogenous retrovirus type K (HML-2) is activated by the Tat protein of HIV-1. J Virol (2012) 1.10
Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation. Proc Natl Acad Sci U S A (1995) 1.10
Selective killing of CD4+ cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population. Proc Natl Acad Sci U S A (1992) 1.09
Impact of mutation type and amplicon characteristics on genetic diversity measures generated using a high-resolution melting diversity assay. J Mol Diagn (2012) 1.08
Human immunodeficiency virus type 1 Vpu has a CD4- and an envelope glycoprotein-independent function. J Virol (1993) 1.07
A functionally essential domain of RFX5 mediates activation of major histocompatibility complex class II promoters by promoting cooperative binding between RFX and NF-Y. Mol Cell Biol (2000) 1.06
Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase. J Virol (1994) 1.06
Murine leukemia virus-based Tat-inducible long terminal repeat replacement vectors: a new system for anti-human immunodeficiency virus gene therapy. J Virol (1996) 1.06
Identification and characterization of a temperature-sensitive mutant of human immunodeficiency virus type 1 by alanine scanning mutagenesis of the integrase gene. J Virol (1995) 1.04
Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1. J Med Chem (2012) 1.02
Glycosylphosphatidylinositol-anchored CD4/Thy-1 chimeric molecules serve as human immunodeficiency virus receptors in human, but not mouse, cells and are modulated by gangliosides. J Virol (1991) 1.02
Bile pigments as HIV-1 protease inhibitors and their effects on HIV-1 viral maturation and infectivity in vitro. Biochem J (1996) 1.02
Cellular and viral specificities of human immunodeficiency virus type 1 vif protein. J Virol (2000) 1.02
Analysis of human immunodeficiency virus matrix domain replacements. Virology (2007) 1.01
The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors. Retrovirology (2008) 1.00
Multiple restrictions of human immunodeficiency virus type 1 in feline cells. J Virol (2007) 1.00
Distinct functions and requirements for the Cys-His boxes of the human immunodeficiency virus type 1 nucleocapsid protein during RNA encapsidation and replication. J Virol (1997) 0.99
Cleavage of the murine leukemia virus transmembrane env protein by human immunodeficiency virus type 1 protease: transdominant inhibition by matrix mutations. J Virol (1998) 0.99
Expression of glucose transporter 1 confers susceptibility to human T-cell leukemia virus envelope-mediated fusion. J Virol (2005) 0.98
Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. PLoS Pathog (2011) 0.97
Engineering human immunodeficiency virus 1 protease heterodimers as macromolecular inhibitors of viral maturation. Proc Natl Acad Sci U S A (1996) 0.97
Constitutive production of nonenveloped human immunodeficiency virus type 1 particles by a mammalian cell line and effects of a protease inhibitor on particle maturation. Antimicrob Agents Chemother (1994) 0.96
The disulfide loop of gp41 is critical to the furin recognition site of HIV gp160. Protein Sci (2007) 0.95
Multiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication. J Virol (1999) 0.94
Human cytomegalovirus inhibits human immunodeficiency virus replication in cells productively infected by both viruses. J Virol (1991) 0.93
Recombinant retroviral systems for the analysis of drug resistant HIV. Nucleic Acids Res (1993) 0.92
A heterologous, high-affinity RNA ligand for human immunodeficiency virus Gag protein has RNA packaging activity. J Virol (2000) 0.92
Expression pattern of HIV-1 coreceptors on T cells: implications for viral transmission and lymphocyte homing. Proc Natl Acad Sci U S A (1997) 0.92
CCR6 ligands inhibit HIV by inducing APOBEC3G. Blood (2009) 0.92
Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication. Proc Natl Acad Sci U S A (1997) 0.92
Construction and characterization of replication-competent simian immunodeficiency virus vectors that express gamma interferon. J Virol (1996) 0.91
In vivo assessment of gene delivery to keratinocytes by lentiviral vectors. J Virol (2002) 0.91
A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology (1973) 127.36
Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet (1982) 54.79
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell (1986) 22.26
Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase. Proc Natl Acad Sci U S A (1981) 22.21
Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science (1987) 12.77
Naturally occurring murine leukemia viruses in wild mice: characterization of a new "amphotropic" class. J Virol (1976) 9.33
Biologic features of HIV-1 that correlate with virulence in the host. Science (1988) 9.06
Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol (1988) 6.76
Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants. J Virol (1990) 6.54
Single amino-acid changes in HIV envelope affect viral tropism and receptor binding. Nature (1989) 5.12
Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses. Science (1990) 4.28
Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc Natl Acad Sci U S A (1989) 4.26
CD4-independent infection of human neural cells by human immunodeficiency virus type 1. J Virol (1989) 2.77
Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol (1990) 2.66
Structure and expression of the herpes simplex virus type 2 glycoprotein gB gene. J Virol (1987) 2.52
Isolation of noninfectious particles containing Rous sarcoma virus RNA from the medium of Rous sarcoma virus-transformed nonproducer cells. Proc Natl Acad Sci U S A (1967) 2.13
Development of disease and virus recovery in transgenic mice containing HIV proviral DNA. Science (1988) 1.79
Frameshift and intragenic suppressor mutations in a Rous sarcoma provirus suggest src encodes two proteins. Cell (1983) 1.72
CD4-independent, productive infection of a neuronal cell line by human immunodeficiency virus type 1. J Virol (1990) 1.64
Phenotypic mixing between human immunodeficiency virus and vesicular stomatitis virus or herpes simplex virus. J Acquir Immune Defic Syndr (1990) 1.42
A murine leukemia virus mutant with a temperature-sensitive defect in membrane glycoprotein synthesis. Cell (1979) 1.34
Selection against expression of the Escherichia coli gene gpt in hprt+ mouse teratocarcinoma and hybrid cells. Mol Cell Biol (1987) 1.03
Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 17.81
Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol (2000) 14.74
DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell (2000) 14.43
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology (1995) 14.30
Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature (1998) 11.41
Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. J Exp Med (1997) 11.01
Signal transduction by lymphocyte antigen receptors. Cell (1994) 10.63
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62
Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol (1995) 7.57
The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: a new member of the immunoglobulin gene family. Cell (1985) 7.16
CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell (1996) 6.52
Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature (1997) 6.23
Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell (1994) 5.92
Requirement for RORgamma in thymocyte survival and lymphoid organ development. Science (2000) 5.78
PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature (2000) 5.48
Packaging system for rapid production of murine leukemia virus vectors with variable tropism. J Virol (1992) 5.31
Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol (1993) 5.30
A new classification for HIV-1. Nature (1998) 5.30
Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol (1997) 5.18
Interaction of the unique N-terminal region of tyrosine kinase p56lck with cytoplasmic domains of CD4 and CD8 is mediated by cysteine motifs. Cell (1990) 4.84
Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. J Virol (1991) 4.74
The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev (1998) 4.38
Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J Exp Med (1999) 4.32
BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol (1991) 4.31
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med (1997) 4.21
Inflammatory chemokine transport and presentation in HEV: a remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues. J Exp Med (2001) 3.96
The isolation and sequence of the gene encoding T8: a molecule defining functional classes of T lymphocytes. Cell (1985) 3.91
Inactivation of Notch 1 in immature thymocytes does not perturb CD4 or CD8T cell development. Nat Immunol (2001) 3.89
A subset of CD4+ thymocytes selected by MHC class I molecules. Science (1994) 3.87
Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol (1999) 3.66
Properties of the depolymerization products of microtubules from mammalian brain. Biochemistry (1974) 3.58
CX3CR1+ interstitial dendritic cells form a contiguous network throughout the entire kidney. Kidney Int (2006) 3.53
The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4. Nature (1988) 3.47
A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med (2001) 3.36
Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J Virol (1997) 3.33
A lineage-specific transcriptional silencer regulates CD4 gene expression during T lymphocyte development. Cell (1994) 3.10
Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5. J Exp Med (1997) 2.99
Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr. J Virol (1995) 2.88
Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol (1998) 2.83
Requirement for association of p56lck with CD4 in antigen-specific signal transduction in T cells. Cell (1991) 2.79
Control of interneuron fate in the developing spinal cord by the progenitor homeodomain protein Dbx1. Neuron (2001) 2.78
Internalization of the human immunodeficiency virus does not require the cytoplasmic domain of CD4. Nature (1988) 2.66
Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. J Virol (1997) 2.59
A block to human immunodeficiency virus type 1 assembly in murine cells. J Virol (2000) 2.47
Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity. Science (1999) 2.45
LyF-1, a transcriptional regulator that interacts with a novel class of promoters for lymphocyte-specific genes. Mol Cell Biol (1991) 2.41
Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases env incorporation into particles and fusogenicity and infectivity. J Virol (1993) 2.34
Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity. J Virol (1992) 2.30
The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest (2001) 2.26
Altered T cell receptor signaling and disrupted T cell development in mice lacking Itk. Immunity (1995) 2.26
Evidence for a stochastic mechanism in the differentiation of mature subsets of T lymphocytes. Cell (1993) 2.25
Cell-cell adhesion mediated by CD8 and MHC class I molecules. Nature (1988) 2.25
The structure of the CD4 and CD8 genes. Annu Rev Immunol (1987) 2.25
The primate lentiviral receptor Bonzo/STRL33 is coordinately regulated with CCR5 and its expression pattern is conserved between human and mouse. J Immunol (2000) 2.22
Analysis of the site in CD4 that binds to the HIV envelope glycoprotein. J Immunol (1990) 2.21
Helper T cells without CD4: control of leishmaniasis in CD4-deficient mice. Science (1993) 2.20
Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology (1998) 2.20
A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2. Nature (1990) 2.17
A kinase-independent function of Lck in potentiating antigen-specific T cell activation. Cell (1993) 2.16
Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD4+ T cells. Immunity (1999) 2.09
The gene encoding the T-cell surface protein T4 is located on human chromosome 12. Proc Natl Acad Sci U S A (1986) 2.08
Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J Virol (1998) 2.03
Epigenetic silencing of CD4 in T cells committed to the cytotoxic lineage. Nat Genet (2001) 1.95
Retracted Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science (1999) 1.93
Viral receptors of the immunoglobulin superfamily. Cell (1989) 1.90
A heterodimer of HEB and an E12-related protein interacts with the CD4 enhancer and regulates its activity in T-cell lines. Mol Cell Biol (1993) 1.89
Regulated expression of human CD4 rescues helper T cell development in mice lacking expression of endogenous CD4. EMBO J (1993) 1.86
Vpu-induced degradation of CD4: requirement for specific amino acid residues in the cytoplasmic domain of CD4. J Virol (1993) 1.86
Regulation of IL-4 expression by activation of individual alleles. Immunity (1998) 1.84
Identification and sequence of a fourth human T cell antigen receptor chain. Nature (1988) 1.81
Unusual intron in the immunoglobulin domain of the newly isolated murine CD4 (L3T4) gene. Nature (1987) 1.78
Polymorphism in the alpha 3 domain of HLA-A molecules affects binding to CD8. Nature (1989) 1.76
Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines. Virology (1998) 1.76
The regulation of CD4 and CD8 coreceptor gene expression during T cell development. Annu Rev Immunol (1999) 1.72
Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J Virol (1998) 1.69
Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol (1998) 1.69
The protein tyrosine kinase p56lck inhibits CD4 endocytosis by preventing entry of CD4 into coated pits. J Cell Biol (1992) 1.67
Chemokine receptor regulation and HIV type 1 tropism in monocyte-macrophages. AIDS Res Hum Retroviruses (1998) 1.62
The cytoplasmic domain of CD4 is sufficient for its down-regulation from the cell surface by human immunodeficiency virus type 1 Nef. J Virol (1994) 1.60
A second subunit of CD8 is expressed in human T cells. EMBO J (1988) 1.55
Mouse-human heterokaryons support efficient human immunodeficiency virus type 1 assembly. J Virol (2001) 1.55
Broad host range of human T-cell leukemia virus type 1 demonstrated with an improved pseudotyping system. J Virol (1996) 1.53
Use of a novel human immunodeficiency virus type 1 reporter virus expressing human placental alkaline phosphatase to detect an alternative viral receptor. J Virol (1995) 1.51
Identification and characterization of a T-cell-specific enhancer adjacent to the murine CD4 gene. Mol Cell Biol (1991) 1.50
An enhancer that directs lineage-specific expression of CD8 in positively selected thymocytes and mature T cells. Immunity (1997) 1.48
Functional and antigenic characterization of human, rhesus macaque, pigtailed macaque, and murine DC-SIGN. J Virol (2001) 1.48
Cloning and characterization of a novel promiscuous human beta-chemokine receptor D6. J Biol Chem (1997) 1.46
Development and function of T cells in mice with a disrupted CD2 gene. EMBO J (1992) 1.46
Cloning of terminal transferase cDNA by antibody screening. Proc Natl Acad Sci U S A (1984) 1.45
Multiple developmental stage-specific enhancers regulate CD8 expression in developing thymocytes and in thymus-independent T cells. Immunity (1998) 1.44
Lymphoid tissue inducer cells in intestinal immunity. Curr Top Microbiol Immunol (2006) 1.38
Segmented filamentous bacteria take the stage. Mucosal Immunol (2010) 1.37
Disruption of T lymphocyte positive and negative selection in mice lacking the CD8 beta chain. Immunity (1994) 1.34
The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins. Virology (1998) 1.33
Insertion of Ia and H-2 alloantigens into model membranes. Proc Natl Acad Sci U S A (1979) 1.31